The StarMS Trial for highly active relapsing remitting multiple sclerosis
Feb 2023: The Anne Rowling Clinic is open for recruitment to the StarMS Clinical Trial.
The StarMS clinical trial led by the University of Sheffield is now open for recruitment at the Anne Rowling Clinic. StarMS is a clinical trial for people living with highly active relapsing-remitting multiple sclerosis (RRMS). The trial aims to compare the efficacy and safety profile of Autologous Haematopoietic Stem Cell Transplantation (aHSCT) versus 'highly effective' Disease Modifying Therapies (DMTs). In total, the StarMS trial aims to recruit 198 participants from across 19 sites in the UK. ) The Edinburgh trial team is led by Professor David Hunt who said:
“StarMS is a very important trial, addressing a critical question about how multiple sclerosis is treated. I am delighted that the Anne Rowling Clinic is a recruiting site and look forward to working with our excellent haematology and neurology teams on this trial.”
There are strict criteria for participation in the trial with patients being able to complete an online questionnaire to see if they are potentially eligible for the trial. Potentially eligible participants will then undergo a number of screening assessments, with each case being reviewed by a central team of neurologists who are involved in the study. This is to ensure that patients only take part in the trial and receive the trial treatment(s) if it is right for them and their condition. Patients who feel they may be eligible and would like to take part in the trial, should contact their treating neurologist in the first instance.